RT Journal Article
SR Electronic
T1 The science of child and adolescent mental health in Brazil: a nationwide systematic review and compendium of evidence-based resources
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.10.24317061
DO 10.1101/2024.11.10.24317061
A1 Marchionatti, Lauro Estivalete
A1 Campello, André Cardoso
A1 Veronesi, Jessica Azevedo
A1 Ziebold, Carolina
A1 Tonon, André Comiran
A1 Casella, Caio Borba
A1 Schafer, Julia Luiza
A1 Madyun, Aaliyah Nadirah
A1 Caye, Arthur
A1 Kieling, Christian
A1 Rohde, Luis Augusto
A1 Polanczyk, Guilherme V.
A1 Mari, Jair
A1 Rocha, Rudi
A1 Rosa, Leonardo
A1 Rosa, Dayana
A1 Sanchez, Zila M
A1 Bressan, Rodrigo A
A1 Saxena, Shekhar
A1 Evans-Lacko, Sara
A1 Cuijpers, Pim
A1 Merikangas, Kathleen R.
A1 Kohrt, Brandon A.
A1 Bantjes, Jason
A1 Reynolds, Shirley
A1 Mneimneh, Zeina
A1 Salum, Giovanni Abrahão
YR 2024
UL http://medrxiv.org/content/early/2024/11/14/2024.11.10.24317061.abstract
AB Background Brazil is home to 50 million children and adolescents, whose mental health needs require context-sensitive research. Although scientific output is growing in the country, publications are scattered and often inaccessible.Methods This systematic review compiles prevalence estimates, assessment instruments, and interventions for child and adolescent mental health in Brazil (PROSPERO registration: CRD42023491393). We searched international (PubMed, Web of Science, PsycINFO, Google Scholar) and national (Scielo, Lilacs, Brazilian Digital Library of Theses and Dissertations) databases up to July 2024. Reference lists, reviews, and experts were consulted. Extraction followed Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) and Cochrane manuals.Results This review appraises 734 studies on 2,576 prevalence estimates, 908 studies on 912 instruments, and 192 studies on 173 intervention trials. Point prevalence of any mental disorder ranged from 10.8% (age 12) to 19.9% (ages 7 to 14), although a nationally-representative study is lacking. There is a rise of self-harm notifications, reaching 133.1 in 2019 (per 100,000 aged 10-19). Indigenous youth face suicide rates of 11 (age 10 to 14), far exceeding national averages (0.652). There is severe violence exposure (21% of adolescents reported domestic physical violence in the previous month), disproportionately impacting Black youth and heightening risks for depression and substance use. Reliable instruments exist for assessing psychopathology, yet most lack psychometric and cross-cultural validation. Interventions remain under-implemented; the largest trials adapted international substance-use prevention programs, showing null effects. High-quality studies are mainly funded by public investment.Discussion This compilation provides accessible data for professionals, facilitating translation of science to practice. Brazilian sociocultural challenges impact youth mental health, with public health priorities including violence, systemic racism, and indigenous youth suicide. National research must develop culturally-sensitive resources for mental health, including scalable interventions focused on social minorities.Funding The Stavros Niarchos Foundation.Competing Interest StatementGuilherme V. Polanczyk has served as a speaker and/or consultant to Abbott, Ache, Adium, Apsen, EMS, Libbs, Medice, Takeda, and receives authorship royalties from Manole Editors. Luis Augusto Rohde has received grant or research support from, served as a consultant to, and served on the speakers' bureau of Abdi Ibrahim, Abbott, Ache, Adium, Apsen, Bial, Cellera, EMS, Knight Therapeutics, Libbs, Medice, Novartis/Sandoz, Pfizer/Upjohn/Viatris, Shire/Takeda, and Torrent in the last three years. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by Dr Rohde have received unrestricted educational and research support from the following pharmaceutical companies in the last three years: Novartis/Sandoz and Shire/Takeda. Dr Rohde has received authorship royalties from Oxford Press and ArtMed. Shekhar Saxena is a senior advisor to McKinsey Health Institute. Arthur Caye served as a consultant for Knight Therapeutics. Rodrigo Bressan received institutional grants, personal fees and non-financial support from Janssen. All other authors declare no conflict of interest. All declared support occurred outside of the present work. Funding StatementFinancial support has been provided by the Stavros Niarchos Foundation (SNF) as part of its Global Health Initiative (GHI) through the SNF Global Center for Child and Adolescent Mental Health at the Child Mind Institute. The funder had no role in the methodology, execution, analyses, or interpretation of the data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript